Daizo Kondo1, Kazumi Ota2, Koji Kasanuki3, Hiroshige Fujishiro2, Yuhei Chiba1, Norio Murayama2, Kiyoshi Sato2, Yoshio Hirayasu4, Heii Arai5, Eizo Iseki6. 1. PET/CT Dementia Research Center, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Japan; Department of Psychiatry, Yokohama City University School of Medicine, Japan. 2. PET/CT Dementia Research Center, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Japan. 3. PET/CT Dementia Research Center, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Japan; Department of Psychiatry, Juntendo University School of Medicine, Japan. 4. Department of Psychiatry, Yokohama City University School of Medicine, Japan. 5. Department of Psychiatry, Juntendo University School of Medicine, Japan. 6. PET/CT Dementia Research Center, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, Japan; Department of Psychiatry, Juntendo University School of Medicine, Japan. Electronic address: eiseki@juntendo.ac.jp.
Abstract
AIM: To determine characteristics of MCI that can predict whether patients will go on to develop AD or DLB. METHODS: Ninety-three patients diagnosed with MCI underwent neuropsychological and neuroimaging examinations, and were followed-up for a mean of 44.9±19.3months. They were divided into four MCI subtypes (amnestic/non-amnestic MCI, single/multiple domain) according to neuropsychological findings, and into three other MCI categories (AD-type PET, DLB-type PET, and unknown-type PET) based on (18)F-fluorodeoxyglucose PET findings. Patients who were eventually diagnosed with AD, DLB, other dementia, or remained MCI were analyzed in relation to the groups to which they had initially been allocated at the MCI stage. RESULTS: Clinical diagnosis after follow-up determined AD in 21 patients (22.6%), DLB in 12 patients (12.9%), other dementia in 2 patients (2.2%), and non-converter in 58 patients (62.3%). Amnestic single-domain MCI and AD-type PET tended to convert into AD. Amnestic multiple-domain MCI and DLB-type PET tended to convert into DLB. A few patients with AD-type PET later developed DLB, and some with DLB-type PET later developed AD. CONCLUSIONS: Predicting which type of dementia a person with MCI will later develop might be possible based on early assessment with clinical symptoms in conjunction with neuropsychological and (18)F-fluorodeoxyglucose PET findings.
AIM: To determine characteristics of MCI that can predict whether patients will go on to develop AD or DLB. METHODS: Ninety-three patients diagnosed with MCI underwent neuropsychological and neuroimaging examinations, and were followed-up for a mean of 44.9±19.3months. They were divided into four MCI subtypes (amnestic/non-amnestic MCI, single/multiple domain) according to neuropsychological findings, and into three other MCI categories (AD-type PET, DLB-type PET, and unknown-type PET) based on (18)F-fluorodeoxyglucose PET findings. Patients who were eventually diagnosed with AD, DLB, other dementia, or remained MCI were analyzed in relation to the groups to which they had initially been allocated at the MCI stage. RESULTS: Clinical diagnosis after follow-up determined AD in 21 patients (22.6%), DLB in 12 patients (12.9%), other dementia in 2 patients (2.2%), and non-converter in 58 patients (62.3%). Amnestic single-domain MCI and AD-type PET tended to convert into AD. Amnestic multiple-domain MCI and DLB-type PET tended to convert into DLB. A few patients with AD-type PET later developed DLB, and some with DLB-type PET later developed AD. CONCLUSIONS: Predicting which type of dementia a person with MCI will later develop might be possible based on early assessment with clinical symptoms in conjunction with neuropsychological and (18)F-fluorodeoxyglucose PET findings.
Authors: Sarah Payne; Jane B Shofer; Andrew Shutes-David; Ge Li; Adrienne Jankowski; Pamela Dean; Debby Tsuang Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Ian G McKeith; Tanis J Ferman; Alan J Thomas; Frédéric Blanc; Bradley F Boeve; Hiroshige Fujishiro; Kejal Kantarci; Cristina Muscio; John T O'Brien; Ronald B Postuma; Dag Aarsland; Clive Ballard; Laura Bonanni; Paul Donaghy; Murat Emre; James E Galvin; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Lawrence S Honig; Manabu Ikeda; James B Leverenz; Simon J G Lewis; Karen S Marder; Mario Masellis; David P Salmon; John Paul Taylor; Debby W Tsuang; Zuzana Walker; Pietro Tiraboschi Journal: Neurology Date: 2020-04-02 Impact factor: 9.910